These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20167173)

  • 21. Rapid-Acting and Human Insulins: Hexamer Dissociation Kinetics upon Dilution of the Pharmaceutical Formulation.
    Gast K; Schüler A; Wolff M; Thalhammer A; Berchtold H; Nagel N; Lenherr G; Hauck G; Seckler R
    Pharm Res; 2017 Nov; 34(11):2270-2286. PubMed ID: 28762200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin glulisine: an evaluation of its pharmacodynamic properties and clinical application.
    Helms KL; Kelley KW
    Ann Pharmacother; 2009 Apr; 43(4):658-68. PubMed ID: 19336657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
    Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
    Heise T; Meiffren G; Alluis B; Seroussi C; Ranson A; Arrubla J; Correia J; Gaudier M; Soula O; Soula R; DeVries JH; Klein O; Bode B
    Diabetes Obes Metab; 2019 Apr; 21(4):1066-1070. PubMed ID: 30565407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects.
    Homko C; Deluzio A; Jimenez C; Kolaczynski JW; Boden G
    Diabetes Care; 2003 Jul; 26(7):2027-31. PubMed ID: 12832307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
    Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
    Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans.
    Clausen TS; Kaastrup P; Stallknecht B
    Diabetes Technol Ther; 2009 Sep; 11(9):575-80. PubMed ID: 19764836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study.
    Bode BW; Garg SK; Norwood P; Morales C; Hardy T; Liu R; Ignaut D
    Diabetes Technol Ther; 2021 Jan; 23(1):41-50. PubMed ID: 32640842
    [No Abstract]   [Full Text] [Related]  

  • 29. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
    Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
    Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Basal insulin replacement and use of rapid-acting insulin analogues in patients with type 1 diabetes.
    Zinman B
    Endocr Pract; 2000; 6(1):88-92. PubMed ID: 11419927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary detection of rapid-acting insulin analogs in healthy humans.
    Judák P; Coppieters G; Lapauw B; Van Eenoo P; Deventer K
    Drug Test Anal; 2020 Nov; 12(11-12):1629-1635. PubMed ID: 32386349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin glulisine: a faster onset of action compared with insulin lispro.
    Heise T; Nosek L; Spitzer H; Heinemann L; Niemöller E; Frick AD; Becker RH
    Diabetes Obes Metab; 2007 Sep; 9(5):746-53. PubMed ID: 17593235
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laboratory and Benchtop Performance of a Mealtime Insulin-Delivery System.
    Dreon DM; Hannon TM; Cross B; Carter BJ; Mercer NS; Nguyen JH; Tran A; Melendez PA; Morales N; Nelson JE; Tan MH
    J Diabetes Sci Technol; 2018 Jul; 12(4):817-827. PubMed ID: 29488399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iatrogenic hypoglycemia in patients with type 2 diabetes: comparison of insulin analog premixes and human insulin premixes.
    Martorella AJ
    Postgrad Med; 2011 Jul; 123(4):7-16. PubMed ID: 21680984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
    Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
    Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of lipoatrophy with Lispro insulin without insulin pump therapy.
    Arranz A; Andia V; López-Guzmán A
    Diabetes Care; 2004 Feb; 27(2):625-6. PubMed ID: 14747261
    [No Abstract]   [Full Text] [Related]  

  • 39. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.
    Pozzilli P; Battelino T; Danne T; Hovorka R; Jarosz-Chobot P; Renard E
    Diabetes Metab Res Rev; 2016 Jan; 32(1):21-39. PubMed ID: 25865292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
    Home PD
    Diabetes Obes Metab; 2012 Sep; 14(9):780-8. PubMed ID: 22321739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.